Molecular Analysis for Personalised Therapy 2017

A joint initiative of Cancer Research UK, UNICANCER and ESMO, this conference will explore clinical interpretation of molecular tests for metastatic cancers. The development of new biotechnologies has revolutionised the applications of personalised therapy in metastatic cancer. It is now possible to perform multigene sequencing for cancer patients, either in clinical trials, or in routine use. Unfortunately, while the technologies are robust, the interpretations of these molecular analyses is still a matter of debate, and there is a need to understand which molecular alterations should be targeted in cancer patients.